NA-Selank vs Selank: Modified vs Original
Here is how these two compounds compare — based on published research, not marketing claims.
NA-Selank
0
Indexed Studies
Preclinical
Evidence Level
None
Human Trials
Not Approved
FDA Status
Selank
88
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
NA-Selank is selank with an N-acetyl group added to the front of the molecule. This modification is designed to improve stability and nasal absorption. The original selank has more published research and Russian clinical approval. The question is whether the modification provides a meaningful practical advantage.
Key Differences
| Attribute | NA-Selank | Selank |
|---|---|---|
| Evidence Level | Preclinical | Animal Studies |
| Category | Modified Anxiolytic Peptide | Anxiolytic Peptide |
| Human Data | No published human studies specific to NA-Selank. Evidence is extrapolated from selank. PSI rates L1. | Russian clinical approval. Multiple human studies. PSI rates L2. |
| Safety Profile | Very limited safety data specific to NA-Selank. Safety profile inferred from selank research. | Approved in Russia. Reported as well-tolerated. No dependence liability. |
| Key Limitations | No independent research. Safety and efficacy assumed based on selank. The modification has not been independently validated. | Most evidence in Russian-language literature. Limited Western replication. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
NA-Selank
Same GABA-ergic and enkephalin-modulating mechanism as selank. The N-acetyl modification improves resistance to enzymatic degradation, potentially increasing bioavailability through nasal administration.
Selank
Modulates GABA-ergic signaling and the enkephalin system. Reduces anxiety without sedation or dependence. Also influences serotonin metabolism and BDNF expression.
Same core mechanism. The N-acetyl modification does not change how selank works once it reaches the brain. It changes how efficiently the peptide survives enzymatic degradation in the nasal cavity and bloodstream. Think of it as armor on the same soldier.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 88 indexed studies. Here are the key findings.
Selank is L2 with Russian regulatory approval and published human studies. NA-Selank is L1 with zero independent research. Every claim about NA-Selank is extrapolated from selank data. The evidence gap is significant.
For evidence-based anxiolytic use, selank has the published data and regulatory history.
For potentially improved nasal bioavailability, NA-Selank's modification is designed for this purpose.
For confidence in what you are using, selank has independent validation.
For theoretical pharmacokinetic advantage, NA-Selank may deliver more active peptide per dose.
Key Limitations
- •NA-Selank has zero published research specific to the modified form.
- •Improved bioavailability is theoretical, not clinically demonstrated.
- •The price premium for NA-Selank may not reflect a proven advantage.
- •Both are limited by their Russian-centric evidence base.
PSI Verdict
SUPPORTED BY EVIDENCE
Selank reduces anxiety through GABA modulation without sedation, supported by Russian clinical approval. The N-acetyl modification on NA-Selank is designed to improve enzymatic stability and bioavailability.
NOT YET ESTABLISHED
NA-Selank's improved bioavailability has not been demonstrated in published studies. Whether the modification produces meaningfully different clinical effects from selank is unknown.
CONFIDENCE LEVEL
Low-moderate for selank. Very low for NA-Selank. If using either, selank has the evidence. NA-Selank is a reasonable hypothesis about improved delivery, but it remains unvalidated.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Selank
"Selank eliminated my anxiety without the side effects of benzodiazepines"Plausible but unproven
"Nasal spray is the best way to take it"Supported by published data
"It stacks well with Semax for cognitive performance"Anecdotal only
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
NA-Selank
Very limited safety data specific to NA-Selank. Safety profile inferred from selank research.
Selank
Approved in Russia. Reported as well-tolerated. No dependence liability.
Selank has clinical safety data. NA-Selank does not. The modification is theoretically safe but unvalidated independently.
WHAT THE RESEARCH SUGGESTS
Selank has the research. NA-Selank has the theoretical advantage. Until independent data validates the modification, selank is the evidence-based choice.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.